Two GLP-1s, One Molecule, Two Different Missed-Dose Rules

It is 9pm on the day after your shot day. You forgot. Now what?

The honest answer is that it depends on which pen is in your hand, and the differences are larger than most people expect. Two products containing the same molecule, dosed the same number of times per week, carry missed-dose instructions written from opposite directions — and on some evenings they give different answers.

Every quotation below is from the manufacturer's current FDA-approved label, with the label's revision date.

The weekly injections

Ozempic (semaglutide), label revised 10 June 2026:

"If a dose is missed, administer OZEMPIC as soon as possible within 5 days after the missed dose."

Five days, counted from the dose you did not take. The rest of the Ozempic schedule — starting dose, titration steps, maintenance — is separate from this rule and worth knowing before you need it.

Wegovy (semaglutide), label revised 30 June 2026:

"If you miss a dose of WEGOVY and the next scheduled dose is more than 2 days away (48 hours), take the missed dose as soon as possible."

and

"If you miss a dose of WEGOVY and the next scheduled dose is less than 2 days away (48 hours), do not administer the dose."

Read those twice. Same active ingredient. Same once-weekly schedule. Ozempic's rule is measured forward from the dose you missed — five days. Wegovy's is measured backward from your next dose — 48 hours of clearance.

On most evenings the two agree. On the evening when your next shot is tomorrow, they do not: Ozempic's five-day window may still be open while Wegovy's instruction is explicitly to skip.

The Wegovy dosing schedule escalates on a fixed calendar, which is part of why the label frames the rule around protecting the next scheduled dose rather than rescuing the missed one.

This is not a contradiction in the pharmacology. It is two labels, written by the same manufacturer at different times for different indications, describing the same drug from opposite ends. But if you switched from one to the other — which plenty of people do — the rule you learned no longer applies, and nothing in the pharmacy bag says so.

Mounjaro (tirzepatide), revised 6 May 2026:

"If a dose is missed, instruct patients to administer MOUNJARO as soon as possible within 4 days (96 hours) after the missed dose."

Zepbound (tirzepatide), revised 6 May 2026:

"If a dose is missed, instruct patients to administer ZEPBOUND as soon as possible within 4 days (96 hours) after the missed dose."

Here the two brands of one molecule do agree — four days, stated identically. Which makes the semaglutide difference more conspicuous, not less. Both follow the same tirzepatide titration schedule, which may be why the wording was kept in step.

Trulicity (dulaglutide), revised 10 August 2026:

"If you miss a dose of TRULICITY, take the missed dose as soon as possible if there are at least 3 days (72 hours) until your next scheduled dose."

"If a dose is missed and the next regularly scheduled dose is due in 1 or 2 days, inform the patient to not administer the missed dose and instead resume TRULICITY with the next regularly scheduled dose."

Trulicity uses the same shape as Wegovy — clearance to the next dose — but sets it at 72 hours rather than 48.

Bydureon BCise (exenatide extended-release):

"If you miss a dose of BYDUREON BCISE, take the missed dose as soon as possible if there are at least 3 days (72 hours) until your next scheduled dose."

Same 72-hour rule as Trulicity. Worth noting: AstraZeneca discontinued Bydureon BCise in the United States in October 2024. If you are still holding one, that is a conversation with your prescriber rather than a refill question — the Bydureon BCise page covers what the discontinuation did and did not change.

The daily injections behave differently

Victoza (liraglutide), revised 17 November 2025:

"Instruct patients who miss a dose of VICTOZA to resume the once daily dosage regimen as prescribed with the next scheduled dose."

Saxenda (liraglutide), revised 15 June 2026:

"Do not take an extra dose of SAXENDA or increase your dose on the following day to make up for your missed dose."

For the daily products there is no catch-up window at all. You skip and resume. Saxenda states the prohibition outright, which suggests enough people tried doubling up that it was worth writing down.

What this actually means

The rule belongs to the product, not to the molecule. Semaglutide is the clearest case: Ozempic and Wegovy are the same drug and their labels frame the same decision from opposite directions. If your prescription changed brands, re-read the leaflet rather than reusing what you knew.

The window is not the same length everywhere. Five days, four days, three days, none. There is no single GLP-1 rule to remember, and any article offering you one has not read the labels.

Never double up. No label in this set permits making up a missed dose by taking two. Saxenda says so outright; the others achieve it by telling you to skip.

Check the revision date. Every quote above carries one, because labels change. Wegovy's was revised in June 2026 and now covers both an injection and a tablet — and the tablet's rule is different again: skip the missed dose and take the next one the following day. An article written before that revision is describing a label that no longer exists in that form.

Where this comes from

Every quotation is from the manufacturer's own Structured Product Label as published on DailyMed, the National Library of Medicine's label repository. We use the manufacturer's label rather than a repackager's copy — a name search returns repackagers first for most of these drugs, and their versions can lag the original by several revisions.

Per-drug dosing schedules, including the full semaglutide escalation, are kept current and dated.

This is information, not medical advice. The missed-dose decision on any particular evening belongs to you and your prescriber — what the labels give you is what the manufacturer committed to in writing, which is a better starting point than a forum thread.